Scientific Generics Limited

Affymetrix, Inc.

Torsana Diabetes Diagnostics A/s

Pna Diagnostics A/s

Microsens Biophage Limited

Amdex A/s

Boehringer Mannheim Gmbh

Elopak Systems Ag

Microsens Medtech Limited

Microsens Biphage Limited

Pad Pharma Limited

Oakville Trading Hong Kong Limited

Christopher John Stanley

Stuart Mark Wilson

Henrik Orum

Anders Weber

Amin Reza Lane

Mikkel Jorgensen

Patricia L Archer

Helge B Castberg

Peter John Hyde

Allan Otto Fog Lihme

Karin Bergmann

Karen Margaret Ness

Ole Basboll

Mikkell Jorgensen

Stuart Wilson

Aggregating proteins such as IgG, are bound selectively in the presence of the non-aggregated protein using a polyionic binding agent such as dextran sulphate or pentosan (anionic), or polyamine compounds such as pDADMAC (cationic) under selective binding conditions including the use of n-lauroylsarcosine at mildly alkaline pH, and may then be assayed.

Binding of aggregated forms of proteins

Micro-organisms, including fungi, viruses and bacteria such asand/or fragments of micro-organisms such as cell wall components present in an aqueous liquid are captured to a solid surface by adding to the liquid a sufficient quantity of a water soluble polymer in the presence of the solid surface to displace the micro-organisms and/or fragments from the liquid to the solid surface. The surface may be provided by a bead. The water soluble polymer may be polyethyleneglycol or polyvinylpyrrolidone.

Capture of micro-organisms

A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample.

Binding of pathological forms of prion proteins

A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.

Treatment of protein aggregation diseases

Infective aggregating forms of proteins such as PrP, amyloid, and tau are bound selectively in the presence of the normal form protein using a polyionic binding agent such as dextran sulphate or pentosan (anionic), or polyamine compounds such as pDADMAC (cationic) under selective binding conditions including the use of n-lauroylsarcosine at mildly alkaline pH, and may then be assayed.

A nucleic acid primer is bound to a soluble carrier macromolecule, a multitude of primer molecules thus being carried by each carrier macromolecule, and hybridisation of the primer to a template followed by extension of the primer to replicate the template in complementary form is carried out as part of a PCR procedure or other amplification, or to form an extended primer of greater hybridisation affinity. A second primer used in the amplification may also be bound to a carrier macromolecule.

Use of nucleic acids bound to carrier macromolecules

An implantable sensor for use in the detection of quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.

Optical sensor for in situ measurement of analytes

A novel preparative methodology yields water-soluble, cross-linked conjugates and conjugate complexes that confer an improved sensitivity in immunochemical assays, particularly in the context of lateral flow devices and in determinations of the presence or absence of small amounts of active components present in a liquid sample.

Method for preparing water-soluble cross-linked conjugates

An implantable sensor for use in the detection or quantitative measurement of an analyte in subcutaneous fluid, the sensor being biodegradable or hydrolysable in vivo. The sensor incorporates an assay for the analyte, the readout of which is a detectable or measurable optical signal which can, when the sensor is in operation in a subcutaneous location, be interrogated transcutaneously by external optical means.

A process is described for denaturing native double-stranded nucleic acid material into its individual strands in an electrochemical cell. The process disclosed is an electrical treatment of the nucleic acid with a voltage applied to the nucleic acid material by an electrode. The process may also employ a promoter compound such as methyl viologen to speed denaturation. The process may be used in the detection of nucleic acid by hybridizing with a labelled probe or in the amplification of DNA by a polymerase chain reaction or ligase chain reaction.

Electrochemical denaturation of double-stranded nucleic acid

A nucleic acid analog comprising a polymeric strand which includes a sequence of ligands bound to a backbone made up of linked backbone moieties, which analog is capable of hybridization to a nucleic acid of complementary sequence, further comprising a chelating moiety capable of binding at least one metal ion by chelation.

Nucleic acid analogs with a chelating functionality

A nucleic acid primer is bound to a soluble carrier macromolecule, a multitude of primer molecules thus being carried by each carrier macromolecule, and hybridisation of the primer to a template followed by extension of the primer to replicate the template in complementary form is carried out as part of a PCR procedure or other amplification, or to form an extended primer of greater hybridization affinity. A second primer used in the amplification may also be bound to a carrier macromolecule.

A process is described for denaturing native double-stranded nucleic acid material into its individual strands in an electrochemical cell. The process disclosed is an electrical treatment of the nucleic acid with a voltage applied to the nucleic acid material by an electrode. The process may also employ a promoter compound such as methyl viologen to speed denaturation. The process may be used in the detection of nucleic acid by hybridizing with a labelled probe or in the amplification of DNA by a polymerase chain reaction or ligase chain reaction. A process is described for annealing complementary strands of nucleic acid by application of an electrical voltage.

Growing community of inventors

Huntingdon, United Kingdom

Christopher John Stanley